levels may be related to the course and outcome in GBS 4 . The neutrophil-to-lymphocyte ratio (NLR) is calculated from the white blood cell count and is a novel prognostic and inflammatory marker in patients with neurological diseases 5, 6 . The platelet-to-lymphocyte ratio (PLR) is a new biomarker of inflammation 7 . The PLR is thought to be a sensitive marker and to be a prognostic factor in many malignancies 8 . Changes in the levels of acute phase reactants, such as albumin, the NLR, and the PLR have not been well studied in patients with GBS. In this study, we aimed to evaluate the albumin level, NLR, and PLR in patients with GBS. We also evaluated the association between disease prognosis and the albumin level, NLR, and PLR.
METHODS
This study was conducted retrospectively in the Neurology Department of Dicle University, Diyarbakir, Turkey. The data for the study were extracted from the medical records of patients who attended the hospital between January 2011 and January 2016. The study included 62 patients with GBS. Demographics, age, sex, clinical features, electrophysiology, subtype, and treatment-related outcomes were assessed. A diagnosis of GBS was based on the criteria of the Brighton Collaboration GBS Working Group All the patients underwent physical and neurological examinations, liver and kidney function tests, and lipid profiling. In all cases, a complete blood count was also obtained, and electrolyte levels were tested. Electromyography (NihonKohden) was performed in each patient. The classification of the patients as having an axonal or demyelinating subtype was based on the electrodiagnostic criteria of Hadden et al.
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, and an AMSAN diagnosis was based on the criteria of Rees et al. 12 .
Exclusion criteria included severe heart failure, autoimmune disease, diabetes mellitus, malignant hypertension, Cushing' s syndrome, central nervous system vasculitis, congenital vascular disease, trauma, dissection, thyroid and kidney dysfunction, liver failure, and local and systemic infection.
Venous blood samples were collected when the patient initially presented to the emergency department or intensive neurology care unit (pretreatment-1) and 96-120 h after the first observation (post-treatment-2). The serum albumin levels were measured using a Beckman Coulter CX9 (Beckman Coulter, Inc., Brea, CA) chemistry analyzer. At our hospital, a serum albumin range of 3.5-5.5 gr/dL is considered normal. Hematologic indices were measured using an automated hematology analyzer system (Abbott Cell-Dyn 3700; Abbott Laboratory, Abbott Park, ILs). All subsequent analyses were based on absolute cell counts. The baseline NLR was measured by dividing the neutrophil count by the lymphocyte count, and the PLR was measured by dividing the platelet count by the lymphocyte count.
Statistical analysis
The statistical analyses were performed using SPSS software, version 20.0 (SPSS Inc., Chicago, IL). Continuous data are presented as mean ± standard deviation (SD). Between-group differences in continuous variables were determined by a Student's t test or the Mann-Whitney U test for variables, with or without a normal distribution, respectively. To test whether the data showed a normal distribution, the Kolmogorov-Smirnov test was used. Categorical variables were summarized as percentages and compared with a one-way ANOVA test. Relationships between the variables were examined by calculating Pearson's and Spearman's correlation coefficients. To find independent associates of the Hughes' score, variables with a p value of ≤ 0.05 in a bivariate correlation analysis and univariate analysis were selected for multiple linear regression analyses. The cut-off values and corresponding sensitivity and specificity values for the prediction of the AIDP based on the serum albumin level, NLR, and PLR were estimated by receiving operator characteristic (ROC) curve analysis. A p value of < 0.05 was accepted as the threshold for determining statistical significance.
RESULTS
Sixty-two patients were enrolled in this study. Of the patients with GBS, 36 were men (58.1%), and 26 were women (41.9%). The mean age of the patient group was 48.0 ± 19.84 . Four of the patients died. Intravenous immunoglobulin was administered to all the patients.
The mean serum albumin levels were 3.58 ± 0.55 (2-4.6) at the first observation (albumin-1), and 30.6% of the patients (n = 19) had hypoalbuminemia. The mean serum albumin levels after 96-120 h (albumin-2) were 3.32 ± 0.59 (1.5-4.5), and 54.8% of the patients (n = 34) had hypoalbuminemia. Three patients were treated with 100 ml of 25% albumin via intravenous infusion. The albumin-1 (baseline/pretreatment) levels were significantly lower than the albumin-2 (post-treatment) levels (p < 0.05). The albumin-1 and -2 levels were negatively correlated with the Hughes' scores (admission/discharge). Thirty-five of the patients had AIDP, 12 had AMAN, and 15 had AMSAN. The Table shows the comparisons of the demographic features and laboratory findings among the subgroups. In the patients with AIDP, the neutrophil-1 and -2 levels (pre-and post-treatment levels, respectively) and NLR-1 (pretreatment) were significantly higher than those of the patients with AMAN and AMSAN. (p < 0.05). The pretreatment PLR (PLR-1) was significantly higher in the patients with AIDP when compared with those with AMAN (p < 0.05) The neutrophil-1 and -2 and lymphocyte-1 (pretreatment) and -2 (post-treatment) levels were significantly higher in the patients with AIDP, as compared to those of the patients with AMSAN (p < 0.05). When the results of the pre-and posttreatment measurements were compared, there were no correlations between the Hughes' scores (admission/discharge) and neutrophil-1 and -2, lymphocyte-1 and -2, platelet-1 and -2, NLR-1-and 2, and PLR-1 (p > 0.05).
A cut-off NLR-1 of 3.275 predicted AIDP, with 83% sensitivity and 93% specificity (ROC area under the curve [AUC] of 0.928, 95% CI, 0.860-0.995, p < 0.001). A cut-off PLR-1 of 121.8 predicted AIDP, with 74% sensitivity and 70% specificity (ROC AUC of 0.761, 95% conficende interval [CI] 0.638-0.883, p < 0.001; Figure) 
DISCUSSION
This study demonstrated that serum albumin levels decreased in GBS patients in the subacute period and that there was a negative correlation between albumin levels and Hughes' scores (admission/discharge). The NLR and PLR increased in AIDP during the acute period. To the best of our knowledge, this is the first clinical study to evaluate the association of GBS subtypes with serum albumin levels and the NLR and PLR.
The serum albumin concentration depends on various factors, such as the synthesis, rate of degradation, distribution, and exogenous loss of albumin, as well as nutritional intake and colloid oncotic pressure changes. The presence of systemic inflammation affects the synthesis of albumin 13, 14, 15, 16 . Albumin is a late-reacting negative acute-phase protein 17 . The present study demonstrated the following: hypoalbuminemia is common in patients with GBS, it decreases after the subacute period, and there is a negative correlation between albumin levels and GBS disability. The mean pre-and post-treatment serum albumin levels of the AIDP group were lower than those of the other groups. Such decreases in mean albumin levels in AIDP are thought to be mainly due to inflammation, hemodilution, or an acute phase response. Pathophysiological changes in GBS depend upon the subtype. Immune reactions directed against epitopes in Schwann cell surface membrane or myelin can cause AIDP
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. Cellular and humoral immune responses participate in these pathophysiological processes, with infiltration of epineural and endoneural small vessels by lymphocytes and monocytes causing segmental myelin degeneration throughout the nerve 19 . In demyelination forms of GBS, Berciano et al. showed that spinal root sections had extensive and almost pure macrophage-associated demyelination, with the occasional presence of T lymphocytes and neutrophil leukocytes 20 . On the other hand, immune reactions against epitopes in the axonal membrane cause AMAN and AMSAN 21 . In these variants of GBS, the axon is affected, without an inflammatory response 21 . The primary immune process is directed at the nodes of Ranvier, leading to functional axonal involvement with conduction block caused by paranodal myelin detachment, node lengthening, sodium channel dysfunction, and altered ion and water homeostasis 22 . These pathophysiological processes may be rapidly reversed in some patients or it may progress to axonal degeneration. Acute motor axonal neuropathy involves the motor nerves of the ventral roots, peripheral nerves, and preterminal intramuscular motor twigs 23 . In AMSAN, sensory nerves are also affected. These pathophysiological processes may increase the importance of lymphocytes and neutrophils as diagnostic features of GBS subtypes. In this study, neutrophilia was detected in AIDP.
According to some studies, the NLR and PLR are new biomarkers of the presence of inflammation 24, 25 . Alan et al. 24 showed that the NLR and PLR might be associated with the presence and severity of Behçet's syndrome. Kokcu et al. 26 reported that the NLR, platelet count, and PLR were elevated in late stages of ovarian cancer. They also claimed that the PLR was an independent prognostic factor of the stage of epithelial ovarian cancer. In the present study, NLR-1 was a statistically significant biomarker in AIDP, and PLR-1 was a statistically significant biomarker in AIDP but not AMAN. When the results of the pretreatment and post-treatment measurements were compared, there were no correlations between the Hughes' scores (admission/discharge) and neutrophil-1 and -2, lymphocyte-1 and -2, platelet-1 and -2, NLR-1 and -2, and PLR-1. The data demonstrated that a pretreatment NLR value of 3.275 predicted the presence of the acute period of AIDP with 83% sensitivity and 93% specificity. A pretreatment PLR of 121.8 predicted the presence of the acute period of AIDP, with 74% sensitivity and 70% specificity.
In conclusion, decreased albumin levels may exacerbate GBS-related disability. Decreased NLRs and PLRs may indicate the presence of AIDP, but they are not associated with the severity of the disease. The NLR may be a useful diagnostic marker of AIDP. Larger prospective studies are needed to support the findings of the present study.
